Market Overview:
The global diabetic therapeutic market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about diabetes and its treatment, and technological advancements in the field of diabetic therapeutics. Based on type, the global diabetic therapeutic market is segmented into sulphonylureas, biguanides, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors and SGLT-2 inhibitors. Sulphonylureas are expected to dominate this market during the forecast period owing to their high efficacy and safety profile. Based on application, the global diabetic therapeutic market is segmented into diagnostic/clinics; ICUs; home healthcare; and other applications (including research institutes). The diagnostic/clinic application segment is expected to account for a major share of this market during the forecast period owing to rising demand for early diagnosis and treatment of diabetes.
Product Definition:
A diabetic therapeutic is a type of medication that helps to manage diabetes. These medications help to lower blood sugar levels and can also help to improve heart health in people with diabetes.
Sulphonylureas:
Sulphonylureas are used for the treatment of type II diabetes. They work by increasing the sensitivity of insulin to glucose and decrease the production of sugar in the liver. The drug class is derived from natural occurring plant derivatives, which were first discovered and developed as anti-cancer agents in 1960s.
Biguanides:
Biguanides are a class of drug used to treat type II diabetes. They were first introduced in the early 1960s and have been an integral part of the treatment algorithm for diabetes ever since. The global biguanides market is expected to witness significant growth over the forecast period owing to increasing prevalence of type II diabetes, rising awareness about its benefits among patients as well as physicians, and growing adoption in emerging countries such as China & India.
Application Insights:
Diagnostic/clinics held the largest share of over 70.0% in 2017. This is owing to the rising prevalence of diabetes and an increase in demand for effective and efficient drugs that cure or manage this disease. The application segment is further divided into diabetic clinics, primary care clinics, specialty clinics, hospitals & laboratories, diagnostic centers and other sites (e.g., schools).
The home healthcare segment is expected to witness lucrative growth during the forecast period due to a rise in incidences of type 2 diabetes across all age groups globally coupled with increasing awareness about early diagnosis.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing region with a CAGR of XX% over the forecast period, owing to rising diabetic population and increasing healthcare expenditure in emerging economies such as India and China. In addition, growing awareness about diabetes treatment options is anticipated to fuel growth during the forecast period. For instance, GlaxoSmithKline (GSK) launched its new drug Patadaylight (sitagliptin/Januvia) in Japan for treating diabetes patients with obesity or overweight conditions. The company intends to launch it globally soon after receiving approval from regulatory agencies such as FDA & EMEA.
North America held a substantial share of around 27% by 2030 owing high prevalence of type 2 diabetes among American population especially youth suffering from obesity coupled with unhealthy lifestyle habits such as smoking.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is mainly due to the changing lifestyle and dietary habits of people across the world. As a result, there is a growing demand for effective diabetic therapies.
- Advances in technology: The field of diabetic therapeutics is constantly evolving with new technologies being developed to improve the treatment and management of diabetes mellitus. This has led to the emergence of novel therapeutic approaches that are more efficacious and safer than traditional therapies.
- Growing awareness about diabetes: There has been a significant increase in public awareness about diabetes in recent years, which has helped to drive demand for better treatments for this condition. People are now more aware of the risks associated with uncontrolled blood sugar levels and are seeking out better therapies to manage their condition effectively.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Therapeutic Market Research Report
By Type
Sulphonylureas, Biguanides, Meglitinides, Thiazolidinediones, Alpha-glucosidase Inhibitors, DPP-4 Inhibitors, SGLT-2 Inhibitors
By Application
Diagnostic/Clinics, ICUs, Home Healthcare
By Companies
Sanofi, Novo Nordisk, MSD, Astrazeneca, Takeda, Novartis, AbbVie, Eli Lilly, North China Pharmaceutical Group Corporation, Huadong Medicine, Dongbao Pharmaceutical, Hisun Pharmacy, KELUN, Ginwa, Tianan Pharmaceutical, Jumpcan Pharmacy, Guangzhou Baiyun Mountain, SHIJIAZHUANG YILING PHARMACEUTICAL, Wanbang Biopharmaceuticals, Gan & Lee, Taloph
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Therapeutic Market Report Segments:
The global Diabetic Therapeutic market is segmented on the basis of:
Types
Sulphonylureas, Biguanides, Meglitinides, Thiazolidinediones, Alpha-glucosidase Inhibitors, DPP-4 Inhibitors, SGLT-2 Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diagnostic/Clinics, ICUs, Home Healthcare
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Novo Nordisk
- MSD
- Astrazeneca
- Takeda
- Novartis
- AbbVie
- Eli Lilly
- North China Pharmaceutical Group Corporation
- Huadong Medicine
- Dongbao Pharmaceutical
- Hisun Pharmacy
- KELUN
- Ginwa
- Tianan Pharmaceutical
- Jumpcan Pharmacy
- Guangzhou Baiyun Mountain
- SHIJIAZHUANG YILING PHARMACEUTICAL
- Wanbang Biopharmaceuticals
- Gan & Lee
- Taloph
Highlights of The Diabetic Therapeutic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sulphonylureas
- Biguanides
- Meglitinides
- Thiazolidinediones
- Alpha-glucosidase Inhibitors
- DPP-4 Inhibitors
- SGLT-2 Inhibitors
- By Application:
- Diagnostic/Clinics
- ICUs
- Home Healthcare
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Therapeutic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic therapeutic is a term used to describe medications and other treatments that are prescribed to people with diabetes. These treatments can help control blood sugar levels, prevent or delay the onset of diabetes complications, and improve the quality of life for those with diabetes.
Some of the key players operating in the diabetic therapeutic market are Sanofi, Novo Nordisk, MSD, Astrazeneca, Takeda, Novartis, AbbVie, Eli Lilly, North China Pharmaceutical Group Corporation, Huadong Medicine, Dongbao Pharmaceutical, Hisun Pharmacy, KELUN, Ginwa, Tianan Pharmaceutical, Jumpcan Pharmacy, Guangzhou Baiyun Mountain, SHIJIAZHUANG YILING PHARMACEUTICAL, Wanbang Biopharmaceuticals, Gan & Lee, Taloph.
The diabetic therapeutic market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Therapeutic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Therapeutic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Therapeutic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Therapeutic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Therapeutic Market Size & Forecast, 2018-2028
4.5.1 Diabetic Therapeutic Market Size and Y-o-Y Growth
4.5.2 Diabetic Therapeutic Market Absolute $ Opportunity
Chapter 5 Global Diabetic Therapeutic Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Diabetic Therapeutic Market Size Forecast by Type
5.2.1 Sulphonylureas
5.2.2 Biguanides
5.2.3 Meglitinides
5.2.4 Thiazolidinediones
5.2.5 Alpha-glucosidase Inhibitors
5.2.6 DPP-4 Inhibitors
5.2.7 SGLT-2 Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Diabetic Therapeutic Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Diabetic Therapeutic Market Size Forecast by Applications
6.2.1 Diagnostic/Clinics
6.2.2 ICUs
6.2.3 Home Healthcare
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Therapeutic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Therapeutic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Diabetic Therapeutic Analysis and Forecast
9.1 Introduction
9.2 North America Diabetic Therapeutic Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Diabetic Therapeutic Market Size Forecast by Type
9.6.1 Sulphonylureas
9.6.2 Biguanides
9.6.3 Meglitinides
9.6.4 Thiazolidinediones
9.6.5 Alpha-glucosidase Inhibitors
9.6.6 DPP-4 Inhibitors
9.6.7 SGLT-2 Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Diabetic Therapeutic Market Size Forecast by Applications
9.10.1 Diagnostic/Clinics
9.10.2 ICUs
9.10.3 Home Healthcare
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Diabetic Therapeutic Analysis and Forecast
10.1 Introduction
10.2 Europe Diabetic Therapeutic Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Diabetic Therapeutic Market Size Forecast by Type
10.6.1 Sulphonylureas
10.6.2 Biguanides
10.6.3 Meglitinides
10.6.4 Thiazolidinediones
10.6.5 Alpha-glucosidase Inhibitors
10.6.6 DPP-4 Inhibitors
10.6.7 SGLT-2 Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Diabetic Therapeutic Market Size Forecast by Applications
10.10.1 Diagnostic/Clinics
10.10.2 ICUs
10.10.3 Home Healthcare
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Diabetic Therapeutic Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Diabetic Therapeutic Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Diabetic Therapeutic Market Size Forecast by Type
11.6.1 Sulphonylureas
11.6.2 Biguanides
11.6.3 Meglitinides
11.6.4 Thiazolidinediones
11.6.5 Alpha-glucosidase Inhibitors
11.6.6 DPP-4 Inhibitors
11.6.7 SGLT-2 Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Diabetic Therapeutic Market Size Forecast by Applications
11.10.1 Diagnostic/Clinics
11.10.2 ICUs
11.10.3 Home Healthcare
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Diabetic Therapeutic Analysis and Forecast
12.1 Introduction
12.2 Latin America Diabetic Therapeutic Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Diabetic Therapeutic Market Size Forecast by Type
12.6.1 Sulphonylureas
12.6.2 Biguanides
12.6.3 Meglitinides
12.6.4 Thiazolidinediones
12.6.5 Alpha-glucosidase Inhibitors
12.6.6 DPP-4 Inhibitors
12.6.7 SGLT-2 Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Diabetic Therapeutic Market Size Forecast by Applications
12.10.1 Diagnostic/Clinics
12.10.2 ICUs
12.10.3 Home Healthcare
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Diabetic Therapeutic Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Diabetic Therapeutic Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Diabetic Therapeutic Market Size Forecast by Type
13.6.1 Sulphonylureas
13.6.2 Biguanides
13.6.3 Meglitinides
13.6.4 Thiazolidinediones
13.6.5 Alpha-glucosidase Inhibitors
13.6.6 DPP-4 Inhibitors
13.6.7 SGLT-2 Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Diabetic Therapeutic Market Size Forecast by Applications
13.10.1 Diagnostic/Clinics
13.10.2 ICUs
13.10.3 Home Healthcare
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Therapeutic Market: Competitive Dashboard
14.2 Global Diabetic Therapeutic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Novo Nordisk
14.3.3 MSD
14.3.4 Astrazeneca
14.3.5 Takeda
14.3.6 Novartis
14.3.7 AbbVie
14.3.8 Eli Lilly
14.3.9 North China Pharmaceutical Group Corporation
14.3.10 Huadong Medicine
14.3.11 Dongbao Pharmaceutical
14.3.12 Hisun Pharmacy
14.3.13 KELUN
14.3.14 Ginwa
14.3.15 Tianan Pharmaceutical
14.3.16 Jumpcan Pharmacy
14.3.17 Guangzhou Baiyun Mountain
14.3.18 SHIJIAZHUANG YILING PHARMACEUTICAL
14.3.19 Wanbang Biopharmaceuticals
14.3.20 Gan & Lee
14.3.21 Taloph
